XXXX , @entity4446 and birth outcome: a population-based cohort study.

@entity1 @entity500 @entity29 @entity600 @entity4446
BACKGROUND: Data on the safety of @entity500 and @entity4446 during pregnancy are very sparse. AIM: To examine the risk of adverse birth outcomes in @entity1 who took up prescriptions for @entity500 or @entity4446 during pregnancy. METHODS: This is a Danish cohort study based on data from a population-based prescription registry, the Danish Birth Registry and the Hospital Discharge Registry. To examine the risk of @entity600 , we included nine pregnancies exposed 30 days before conception or during the first trimester. To examine perinatal mortality, pre-term birth and low birth weight, we included 10 pregnancies exposed during the entire pregnancy. Eleven different exposed @entity1 were included in the study. Outcomes were compared with those of 19 418 pregnancies in which no drugs were prescribed to the mothers. RESULTS: Fifty-five per cent of the exposed @entity1 had @entity29 and 45% other diseases. Adjusted odds ratios for @entity600 , perinatal mortality, pre-term birth and low birth weight were 6.7 (95% confidence interval, 1.4-32.4), 20.0 (2.5-161.4), 6.6 (1.7-25.9) and 3.8 (0.4-33.3), respectively. CONCLUSIONS: Our results suggest that there is an increased risk of @entity600 , perinatal mortality and pre-term birth in @entity1 born to @entity1 treated with @entity500 or @entity4446 during pregnancy. More data are needed to determine whether the associations are causal or occur through confounding.
